FDA Clearance and CL...
US FDA CLIA-waiver f...
20th March 2023 Content supplied by: bioMérieux (Clinical Diagnostics)
BioFire Defense Partners With BARDA
The BARDA contract supports the expansion of the SPECIFIC REVEAL™ Rapid AST System test menu to include other sample types starting with Gram-negative isolates with contract options to expand the menu to include Gram-positive blood culture and Gram-positive isolates. The contract is one component of the BARDA’s Detection Diagnostics and Devices Infrastructure Division (DDDI) medical countermeasure portfolio.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50122C0005.
Click here to read the full release or use the Request Information button below to contact bioMérieux directly.
Tags:
Date Published: 20th March 2023
Source article link: View
FDA Clearance and CLIA-waiver for
US FDA CLIA-waiver for BIOFIRE&
bioMérieux (Clinical Diagnostics)
Address:
Marcy L'Etoile
France
Related news from bioMérieux (Clinical Diagnostics)
- BIOFIRE® SPOTFIRE® Respiratory/Sore Throat Panel Mini Receives FDA Special Clearance and CLIA Waiver
- bioMérieux's AST System VITEK® REVEAL Achieves FDA 510(k) Clearance
- FDA Clearance and CLIA-waiver for bioMerieux's BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
- US FDA CLIA-waiver for BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
- FDA Clearance and CLIA-waiver for Fast and Innovative BIOFIRE® SPOTFIRE® POC System
- MAESTRIA™, a New Generation Microbiology Middleware Optimizes Laboratory Workflow
- VIDAS® KUBE™ - the Next-generation VIDAS® System Receives CE Marking
- FDA Breakthrough Device Designation for SPECIFIC REVEAL® Rapid AST System
- Added Medical Value with Urine Sample Results Up to 8 Hours Faster
- bioMérieux to Distribute Specific Diagnostics’ REVEAL Rapid AST System in Europe
- Enhanced BIOFIRE® Blood Culture Identification 2 (BCID2) Panel Submitted for FDA Clearance
- Spotlight on Antimicrobial Stewardship with bioMérieux
- New FDA Clearance for VITEK® MS: Expanded ID for Challenging Pathogens
- PhenoMATRIX™ for WASPLab®: AI for Sample Interpretation & Sorting
- BIOFIRE® FILMARRAY® Pneumonia Panels Gain FDA clearance and CE Marking
- bioMérieux and DIAGNOSTICS IS POWER at ECCMID 2018
- FDA Clears Identification of Mycobacteria, Nocardia and Moulds on VITEK® MS
- FDA Clearance for BacT/ALERT® VIRTUO™ Fully Automated Blood Culture System
- bioMérieux Your Expert in Infectious Diseases at ECCMID 2017
- bioMérieux Awarded Multi-year Agreement with NHS for Bacterial Screening of Platelets